Key result
Residence in states with hepatitis A vaccination recommendations was associated with a significantly higher seroprevalence of anti-HAV among U.S.-born children compared to non-vaccinating states (33.8% vs 11.0%; OR 3.8).
Why the study?
Does residence in states with hepatitis A vaccination recommendations increase anti-HAV seroprevalence in the U.S. population?
Population
U.S. civilian noninstitutionalized household population aged ≥6 years sampled in the National Health and…
Comparison
Residence in 17 states with 1999 Advisory… vs Residence in 33 states without hepatitis A…
Design
Cross-sectional
Authors
Loading...
Supports association of recommendations with higher childhood seroprevalence; hypothesis-generating and requires prospective studies before informing policy.
Cross-Sectional (n=51,118)
Does residence in states with hepatitis A vaccination recommendations increase anti-HAV seroprevalence in the U.S. population?
Odds Ratio: 3.8 (95% CI 2.4–6)
Absolute Event Rate: 33.8% vs 11%
p-value: p=<0.001
The 1999 hepatitis A vaccination recommendations were associated with a significant increase in population immunity among children in states where vaccination was recommended.
Klevens et al. (2011) conducted a cross-sectional in Hepatitis A Virus (HAV) antibodies (n=51,118). Residence in vaccinating states vs. Residence in non-vaccinating states was evaluated on Anti-HAV seroprevalence in U.S.-born children aged 6-19 years (1999-2006) (OR 3.8, 95% CI 2.4-6.0, p=<0.001). Residence in states with hepatitis A vaccination recommendations was associated with a significantly higher seroprevalence of anti-HAV among U.S.-born children compared to non-vaccinating states (33.8% vs 11.0%; OR 3.8).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: